OBJECTIVE: To study the impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection on clinically significant transaminase elevation during short-course anti-tuberculosis treatment. DESIGN: Retrospective observation study. RESULTS: During standard anti-tuberculosis treatment of 295 patients with active pulmonary tuberculosis (TB) and normal baseline liver biochemical tests, 25 (8.5%) developed hepatitis and had a significantly higher mortality rate (32% vs. 7%, OR 6.22, 95%CI 2.0-17.6, P = 0.001). Multivariate analysis showed that HCV co-infected individuals were more likely to develop transaminase elevations (OR 3.43, 95%CI 1.14-10.35, P = 0.03) than those without HCV co-infection. They also had a longer duration of transaminase elevation than controls (43.3 +/- 40.4 vs. 13.5 +/- 8.6 days, P = 0.01). Co-infection with HBV was not associated with a higher rate of hepatitis but was associated with later onset (102 +/- 68.7 vs. 37.0 +/- 31.9 days, P = 0.01), higher peak alanine aminotransferase level and slower recovery (55.5 +/- 62.9 vs. 15.4 +/- 10.8 days, P = 0.01). CONCLUSION: Even with normal baseline liver biochemical tests, HCV co-infection had a higher incidence and longer exacerbations of hepatitis during anti-tuberculosis treatment. We suggest that screening for HCV infection before starting anti-tuberculosis treatment is helpful in planning the frequency of follow-up visits.
OBJECTIVE: To study the impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection on clinically significant transaminase elevation during short-course anti-tuberculosis treatment. DESIGN: Retrospective observation study. RESULTS: During standard anti-tuberculosis treatment of 295 patients with active pulmonary tuberculosis (TB) and normal baseline liver biochemical tests, 25 (8.5%) developed hepatitis and had a significantly higher mortality rate (32% vs. 7%, OR 6.22, 95%CI 2.0-17.6, P = 0.001). Multivariate analysis showed that HCV co-infected individuals were more likely to develop transaminase elevations (OR 3.43, 95%CI 1.14-10.35, P = 0.03) than those without HCV co-infection. They also had a longer duration of transaminase elevation than controls (43.3 +/- 40.4 vs. 13.5 +/- 8.6 days, P = 0.01). Co-infection with HBV was not associated with a higher rate of hepatitis but was associated with later onset (102 +/- 68.7 vs. 37.0 +/- 31.9 days, P = 0.01), higher peak alanine aminotransferase level and slower recovery (55.5 +/- 62.9 vs. 15.4 +/- 10.8 days, P = 0.01). CONCLUSION: Even with normal baseline liver biochemical tests, HCV co-infection had a higher incidence and longer exacerbations of hepatitis during anti-tuberculosis treatment. We suggest that screening for HCV infection before starting anti-tuberculosis treatment is helpful in planning the frequency of follow-up visits.
Authors: Jennifer D Hosford; Michael E von Fricken; Michael Lauzardo; Myron Chang; Yunfeng Dai; Jennifer A Lyon; John Shuster; Kevin P Fennelly Journal: Tuberculosis (Edinb) Date: 2014-12-18 Impact factor: 3.131
Authors: Russell R Kempker; Wael A Alghamdi; Mohammad H Al-Shaer; Gena Burch; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2019-10-07 Impact factor: 5.191
Authors: Hesam Ahmadi Nooredinvand; David W Connell; Mahmoud Asgheddi; Mohammed Abdullah; Marie O'Donoghue; Louise Campbell; Melissa I Wickremasinghe; Ajit Lalvani; Onn Min Kon; Shahid A Khan Journal: World J Gastroenterol Date: 2015-08-07 Impact factor: 5.742
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079
Authors: G Bushnell; N L Stennis; A M Drobnik; D C Proops; S D Ahuja; K Bornschlegel; J Fuld Journal: Epidemiol Infect Date: 2014-11-12 Impact factor: 4.434